Treatment of chronic bacterial prostatitis

Area of Science:

• Urology
• Infectious Diseases
• Pharmacology

Background:

• Chronic bacterial prostatitis (CBP) is a prostate infection often caused by Escherichia coli.
• Symptoms can mimic acute urinary tract infections, complicating diagnosis.
• Accurate diagnosis relies on simultaneous quantitative urine cultures.

Purpose of the Study:

• To review the pathogenesis, clinical presentation, diagnosis, and treatment of chronic bacterial prostatitis.
• To evaluate the efficacy of various antibiotic treatments for CBP.
• To identify optimal therapeutic agents for CBP.

Main Methods:

• Review of existing literature on chronic bacterial prostatitis.
• Analysis of antibiotic penetration into prostatic fluid.
• Evaluation of cure rates for different treatment regimens.

Main Results:

• Trimethoprim-sulfamethoxazole shows limited efficacy (around 40% cure rate) due to poor penetration into alkaline prostatic fluid.
• Carbenicillin indanyl sodium demonstrated cure rates nearing 70% in limited studies.
• Erythromycin achieved an 88% cure rate in one study.
• Kanamycin, streptomycin, doxycycline, and minocycline have also been used with varying success or data limitations.

Conclusions:

• Carbenicillin indanyl sodium and erythromycin appear to be superior choices for CBP treatment over trimethoprim-sulfamethoxazole.
• Further comparative trials are needed, but current evidence suggests these agents offer better outcomes.
• Trimethoprim-sulfamethoxazole should be reserved for cases where other treatments are not tolerated or are ineffective.